Shanghai Fosun Pharmaceutical (Group) Co (HK:2196) has released an update.
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. has announced that its subsidiary, Chongqing Carelife Pharmaceutical Co., Ltd., has had its new drug registration application for sodium thiosulfate injection accepted by the National Medical Products Administration. The drug, aimed at treating various poisonings including cyanide and heavy metals, marks a significant milestone in the company’s independent research and development, with an investment of around RMB1.07 million to date.
For further insights into HK:2196 stock, check out TipRanks’ Stock Analysis page.
